Federal Register / Vol. 70, No.
72 / Friday, April 15, 2005 / Notices
Bureau; Bureau of Health Professions;
Healthcare Systems Bureau; HIV/AIDS
Bureau; and Office of Performance
Review.
This notice is to reflect the Order of
Succession for the HRSA.
Section R–30, Order of Succession
During the absence or disability of the
Administrator or in the event of a
vacancy in the office, the first official
listed below who is available shall act
as Administrator, except that during a
planned period of absence, the
Administrator may specify a different
order of succession. The order of
succession will be as such:
1. Deputy Administrator;
2. Associate Administrator, Office of
Administration and Financial
Management;
3. Associate Administrator, Bureau of
Primary Health Care;
4. Associate Administrator, Bureau of
Health Professions;
5. Associate Administrator, HIV/AIDS
Bureau;
6. Associate Administrator, Maternal
and Child Health Bureau;
7. Associate Administrator,
Healthcare Systems Bureau; and
8. Associate Administrator, Office of
Performance Review.
Section R–40, Delegation of Authority
All delegations and redelegations of
authorities to officers and employees of
the Health Resources and Services
Administration which were in effect
immediately prior to the effective date
of this action will be continued in effect
in them or their successors, pending
further redelegation, provided they are
consistent with this action.
This document is effective upon date
of signature.
Dated: April 8, 2005.
Elizabeth M. Duke,
Administrator.
[FR Doc. 05–7551 Filed 4–14–05; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Child Health and
Human Development; Notice of
Meeting
Pursuant to section 10(a) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of a meeting of the
National Advisory Board on Medical
Rehabilitation Research.
The meeting will be open to the
public, with attendance limited to space
VerDate jul<14>2003 17:10 Apr 14, 2005 Jkt 205001
19963
available. Individuals who plan to
attend and need special assistance, such
as sign language interpretation or other
reasonable accommodations, should
notify the Contact Person listed below
in advance of the meeting:
Name of Committee: National Advisory
Board on Medical Rehabilitation Research.
Date: May 2–3, 2005.
Time: May 2, 2005, 8:30 a.m. to 5 p.m.
Agenda: NICHD Director’s Report
presentation, Regional Research Networks,
and an update on the Rehabilitation
Medicine Scientist Training Program.
Place: Holiday Inn—Silver Spring, 8777
Georgia Avenue, Silver Spring, MD 20910.
Time: May 3, 2005, 8:30 a.m. to 12 p.m.
Agenda: Other business dealing with the
NABMRR Board.
Place: Holiday Inn—Silver Spring, 8777
Georgia Avenue, Silver Spring, MD 20910.
Contact Person: Ralph M. Nitkin, PhD,
Director, BSCD, National Center for Medical
Rehabilitation Research, National Institute of
Child Health and Human Development, NIH,
6100 Building, Room 2A03, Bethesda, MD
20892, (301) 402–4206.
This notice is being published less than 15
days prior to the meeting due to the urgent
need to meet training limitations imposed by
the intramural research review cycle.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Information is also available on the
Institute’s/Center’s home page: http://
www.nichd.nih.gov/about/ncmrr.htm, where
an agenda and any additional information for
the meeting will be posted when available.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
93.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS).
Dated: April 7, 2005.
Anna P. Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–7545 Filed 4–14–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institutes of Alcohol Abuse
and Alcoholism; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
PO 00000 Frm 00045 Fmt 4703 Sfmt 4703 E:\FR\FM\15APN1.SGM
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Alcohol Abuse and Alcoholism Special
Emphasis Panel ZAA1 CC34—R01 GRANT
APPLICATION.
Date: May 3, 2005.
Time: 2 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 5635
Fishers Lane, 3041, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Mahadev Murthy, PhD,
MBA, Scientific Review Administrator,
Extramural Project Review Branch, Office of
Extramural Activities, National Institute on
Alcohol Abuse and Alcoholism, MSC 9304,
Room 3037, Bethesda, MD 20892–9304, (301)
443–0800, mmurthy@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.271, Alcohol Research
Career Development Awards for Scientists
and Clinicians; 93.272, Alcohol National
Research Awards for Research Training;
93.273, Alcohol Research Programs; 93.891,
Alcohol Research Center Grants, National
Institutes of Health, HHS)
Dated: April 8, 2005.
Anna P. Snouffer,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–7546 Filed 4–14–05 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Child Health and
Human Development; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), as amended.
The grant applications and the
discussions could disclose confidential
15APN1
 19964 Federal Register / Vol. 70, No. 72 / Friday, April 15, 2005 / Notices
trade secrets or commercial property
such as patentable material, and
personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwrranted
invasion of personal privacy.
Name of Committee: National Institute of
Child Health and Human Development
Special Emphasis Panel Arousal and
Attention Regulation in High Risk Children.
Date: April 27, 2005.
Time: 3:30 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6100
Executive Boulevard, Room 5B01, Rockville,
MD 20852, (telephone conference call).
Contact Person: Marita R. Hopmann, PhD,
Scientific Review Administrator, Division of
Scientific Review, National Institute of Child
Health and Human Development, 6100
Building, Room 5B01, Bethesda, MD 20892,
(301) 435–6911, hopmannm@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.864, Population Research;
98.865, Research for Mothers and Children;
93.929, Center for Medical Rehabilitation
Research; 93.209, Contraception and
Infertility Loan Repayment Program, National
Institutes of Health, HHS).
Dated: April 8, 2005.
Anna P. Snouffler,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–7547 Filed 4–14–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
License: Therapeutics for the
Treatment of Retinopathy
AGENCY: National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
SUMMARY: This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
Part 404.7(a)(1)(i), announces that the
National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive license to practice the
inventions embodied in 1. E–223–1992/
0–US–01, ‘‘SIGNAL TRANSDUCTION
INHIBITOR COMPOUNDS’’, by Elise
Kohn, Lance Liotta, Christian Felder,
issued Pat No. 5,359,078 (issue date
October 25, 1994); 2. E–223–1992/0–
US–02, ‘‘SIGNAL TRANSDUCTION
INHIBITOR TRIAZOLE AND DIAZOLE
VerDate jul<14>2003 14:34 Apr 14, 2005 Jkt 205001
COMPOUNDS’’ by Elise Kohn, Lance
Liotta, Christian Felder, issued Pat No.
5,482,954 (issue date January 9, 1996);
3. E–223–1992/0–US–03, ‘‘SIGNAL
TRANSDUCTION INHIBITOR 1,2,3,-
TRIAZOLO COMPOUNDS’’ by Elise
Kohn, Lance Liotta, Christian Felder,
issued Pat No. 5,498,620, (issued date
March 12, 1996); 4. E–223–1992/0–US–
04, ‘‘SIGNAL TRANSDUCTION
INHIBITOR COMPOUNDS’’ by Elise
Kohn, Lance Liotta, Christian Felder,
issued Pat No 5,705,514 (issued date
January 6, 1998); 5. E–223–1992/0–US–
05, ‘‘SIGNAL TRANSDUCTION
INHIBITOR COMPOUNDS’’ by Elise
Kohn, Lance Liotta, Christian Felder,
issued Pat No 5,880,129 (issued date
March 9, 1999); 6. E–068–1991/1–US–
01, ‘‘METHOD FOR INHIBITING
METALLOPROTEINASE EXPRESSION’’
by Elise Kohn, Lance Liotta, issued Pat
No. Pat No. 5,602,156 (issued date
February 11, 1997); 7. E–220–1993/1–
US–01 ‘‘METHOD FOR INHIBITING
ANGIOGENESIS’’ by Elise Kohn, Lance
Liotta and Riccardo Alessandro issued
patent No 5,744,492 (issue date April
28,1998), to RFE Pharma, having a place
of business in Framingham, MA. The
patent rights in these inventions have
been assigned to the United States of
America.
The prospective exclusive license
territory may be worldwide, and the
field of use may be limited to
therapeutics for the treatment of
retinopathy.
DATES: Only written comments and/or
license applications which are received
by the National Institutes of Health on
or before June 14, 2005, will be
considered.
ADDRESSES: Requests for copies of the
patent and/or patent applications,
inquiries, comments and other materials
relating to the contemplated exclusive
license should be directed to: John
Stansberrry, Ph.D., Technology
Licensing Specialist, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
telephone: (301) 435–5236; Facsimile:
(301) 402–0220; e-mail:
stansbej@mail.nih.gov.
SUPPLEMENTARY INFORMATION: The
present invention provides composition
of matter claims and methods for
inhibiting angiogenesis in a host using
carboxyamido-triazole (CAI) and related
analogs. The calcium influx inhibitor
and matrix metalloproteinase
expression inhibitor, CAI, has shown
anti-cancer activity due to its ability to
influence signal transduction pathways.
CAI and CAI analogues inhibit
PO 00000 Frm 00046 Fmt 4703 Sfmt 4703 E:\FR\FM\15APN1.SGM
endothelial cell adhesion and migration
in response to basement membrane
components and thus block new vessel
formation. Pharmaceutical applications
directed to inhibiting angiogenesis offer
novel approaches to the treatment of
cancer, diabetic retinopathy,
hemangiomata, vasculidities and other
diseases associated with angiogenesis.
The prospective exclusive license will
be royalty-bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR 404.7. The prospective
exclusive license may be granted unless
within sixty (60) days from the date of
this published notice, the NIH receives
written evidence and argument that
establish that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
Dated: April 6, 2005.
Steven M. Ferguson,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 05–7542 Filed 4–14–05; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Methods for Treating
Inflammatory Bowel Disease Using
Cholera Toxin B Subunit
AGENCY: National Institutes of Health,
Public Health Service, DHHS.
ACTION: Notice.
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in U.S. Patent Application
10/129,907, filed May 10, 2002 [DHHS
Ref. E–263–1999/0–US–03], entitled
‘‘Methods for treating inflammatory
bowel disease using cholera toxin B
subunit,’’ to SBL Vaccin AB, which is
located in Stockholm, Sweden. The
patent rights in these inventions have
15APN1